e138 860
[8]
McConkey DJ, Choi W, Shen Y, et al. A prognostic gene expression signature in the molecular classification of chemotherapy-naive urothelial cancer is predictive of clinical outcomes from neoadju- vant chemotherapy: a phase 2 trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with bevacizumab in urothelial cancer. Eur Urol 2016;69:855–62.[9]
Seiler R, Ashab HA, Erho N, et al. Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and surviv- al after neoadjuvant chemotherapy. Eur Urol 2017;72:544–54.[10]
Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second- line therapy for advanced urothelial carcinoma. N Engl J Med 2017;376:1015–26.[11]
Powles T, Smith K, Stenzl A, Bedke J. Immune checkpoint inhibition in metastatic urothelial cancer. Eur Urol 2017;72:477–81.
[12]
Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016;387:1909–20.[13]
Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 2017;389:67–76.
Thomas Powles*
Alfonso
[1_TD$DIFF]
Go´mez de
[6_TD$DIFF]
Lian˜o
Charlotte Ackerman
Department of Oncology, Barts Cancer Institute, London, UK
*Corresponding author. Barts Cancer Institute, Oncology, Charterhouse
Square, London EC1M 6BQ, UK. Tel. +44 7932048109.
E-mail address:
thomas.powles@bartshealth.nhs.uk(T. Powles).
May 15, 2017
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) e 1 3 7 – e 1 3 8
e138